Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness

作者：Li, Changzheng; Wu, Binghuo; Li, Yishan; Liu, Yaxi; Wang, Jin; Xie, Jiayi; Xu, Xi; Tian, Xiaobin; Ye, Zhitao; Guan, Jingjing; Chen, Jie; Xie, Siyu; Zhang, Baolin; Cai, Boyong; Wang, Qianhao; Yu, Haopeng; Lan, Tian; Man, Cheuk Him; Kang, Xunlei; Qian, Pengxu; Perry, John M.; He, Aibin; Jiang, Linjia; Zhao, Meng^*

来源：Blood, 2022, 140(15): 1686-1701.

DOI：10.1182/blood.2022016112

• NUCLEAR-CYTOPLASMIC TRAFFICKING
• BONE-MARROW
• OXYGEN
• QUIESCENCE
• S1P
• HOMEOSTASIS
• BLOOD
• TRANSPLANTATION
• MOBILIZATION
• MAINTENANCE

Hematopoietic stem cells (HSCs) have reduced capacities to properly maintain and replenish the hematopoietic system during myelosuppressive injury or aging. Expanding and rejuvenating HSCs for therapeutic purposes has been a long-sought goal with limited progress. Here, we show that the enzyme Sphk2 (sphingosine kinase 2), which generates the lipid metabolite sphingosine-1-phosphate, is highly expressed in HSCs. The deletion of Sphk2 markedly promotes self-renewal and increases the regenerative potential of HSCs. More importantly, Sphk2 deletion globally preserves the young HSC gene expression pattern, improves the function, and sustains the multilineage potential of HSCs during aging. Mechanistically, Sphk2 interacts with prolyl hydroxylase 2 and the Von HippelLindau protein to facilitate HIF1a ubiquitination in the nucleus independent of the Sphk2 catalytic activity. Deletion of Sphk2 increases hypoxic responses by stabilizing the HIF1a protein to upregulate PDK3, a glycolysis checkpoint protein for HSC quiescence, which subsequently enhances the function of HSCs by improving their metabolic fitness; specifically, it enhances anaerobic glycolysis but suppresses mitochondrial oxidative phosphorylation and generation of reactive oxygen species. Overall, targeting Sphk2 to enhance the metabolic fitness of HSCs is a promising strategy to expand and rejuvenate functional HSCs.

• 单位
  北京大学; 四川大学; 1; 广东药学院; 中山大学; 浙江大学